gestonorone-caproate and Ovarian-Neoplasms

Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Gestonorone Caproate; Humans; Methotrexate; Middle Aged; Ovarian Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms

As previously reported, ovarian epithelial carcinomas may respond to endocrine therapy. We examined the direct effect of progesterone, medroxyprogesteroneacetate, gestoneron, 17-beta-estradiol, tamoxifen, 4-OH-tamoxifen, or N-desmethyltamoxifen on the proliferative capacity of ovarian carcinoma cells by means of the colony assay described by Hamburger and Salmon. The growth rate of 25 tested tumors (ascitic fluid, primary tumor, metastases) was 68%. The plating efficiency was 0.078%. Beside the drug testing estrogen and progesterone receptor levels were determined. The inhibition of colony survival was slightest with 17-beta-estradiol, more pronounced with medroxyprogesteroneacetate, gestoneron, N-desmethyltamoxifen, and progesterone, and greatest with 4-OH-tamoxifen and tamoxifen. Significant and dose-dependent inhibition of greater than 70% was observed with tamoxifen and 4-OH-tamoxifen in 80% of the tested tumors. There was no significant correlation between the in vitro responsiveness and the level of hormonal act not only via an estrogen receptor but also via an antiestrogen-binding site.

Topics: Adenocarcinoma; Aged; Cell Division; Cells, Cultured; Estradiol; Estrogen Antagonists; Ethanol; Female; Gestonorone Caproate; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Ovarian Neoplasms; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen

The human tumor colony forming assay was used to evaluate the response of ovarian carcinoma cells from primary tumors, ascitic fluids and metastasis to hormonal treatment. In 12/35 patients a sufficient colony formation (greater than 30 colonies/dish) was obtained in order to perform a simultaneous drug testing. The plating efficiency of the metastatic samples (0.12%) was significantly higher (P less than 0.053) than those from the primary tumor (0.076%) or those that were derived from the ascitic fluid (0.082%). Colonies from the metastatic tissues could be evaluated 2-4 days earlier than those from primary tumors. These discrepancies may be due to a heterogeneity in the clonable tumor cell compartment of primary tumor and metastasis. The antiproliferative properties of the antiestrogen tamoxifen and the progestin gestoneron were studied. In 9/12 cases a significant, dose-dependent reduction of colony formation (greater than 70-90% of the controls) was observed after continuous exposure to 1 mumole tamoxifen. No correlation between the dose response and the content of steroid receptors was found. Even estrogen receptor negative tumor samples showed a maximal antiproliferative effect of tamoxifen.

Topics: Abdominal Neoplasms; Ascitic Fluid; Clone Cells; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Female; Gestonorone Caproate; Humans; Mitosis; Ovarian Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen

Guanosine 3':5'-phosphate (cycle GMP) in urine has been used to monitor the response of patients with ovarian cancer to treatment. Changes in the cyclic GMP level appear to correlate well with clinical status in that the disappearance of clinically detectable tumour is associated with a drop in the level whereas a tumour recurrence is associated with an elevation. Serially measured cyclic GMP is valuable for detecting a recurrence of tumour growth in patients in clinical remission and can predate any clinical signs by as much as 10 months. In patients who show no response to treatment, cyclic GMP levels in urine are elevated in the majority of specimens collected.

Topics: Creatinine; Cyclic GMP; Cyclophosphamide; Cystadenocarcinoma; Drug Therapy, Combination; Female; Gestonorone Caproate; Humans; Levamisole; Neoplasm Recurrence, Local; Ovarian Neoplasms

Topics: Adenocarcinoma; Adult; Aged; Female; Gestonorone Caproate; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Ovarian Neoplasms

Fifty-four patients with advanced cystadenocarcinoma of the ovary were treated with gestronol (Depostat), 200 mg/week, by intramuscular injection and continuous oral cyclophosphamide, the dose of the latter being varied to maintain the patient's white cell count at about 1.5 x 10(9)/l. A combined partial and complete remission rate of 76 per cent was obtained. The length of survival depended upon the type of remission and the type of remission was markedly affected by the amount of tumour removed at initial laparotomy.

Topics: Cyclophosphamide; Cystadenocarcinoma; Drug Therapy, Combination; Female; Gestonorone Caproate; Humans; Leukocyte Count; Neoplasm Staging; Ovarian Neoplasms

The deoxyribonucleic acid (DNA) synthesis of 12 ovarian tumours was studied by means of short term organ tissue culture, exposure to tritiated thymidine and subsequent autoradiography and visual grain counting. The DNA synthesis in each tumour was studied before and after exposure to 12 separate hormone combinations. It was found that any combination of 17 beta-oestradiol with either of the two progestogens used had greater inhibitory potential than when any of three hormones tested was used alone.

Topics: Aged; Culture Techniques; DNA, Neoplasm; Estradiol; Female; Gestonorone Caproate; Humans; Middle Aged; Ovarian Neoplasms; Progesterone